Cell growth inhibition, G2M cell cycle arrest, and apoptosis induced by the novel compound Alternol in human gastric carcinoma cell line MGC803

Investigational New Drugs

Volumn 25, Issue 6, 2007, Pages 505-517

  Liu, Xia ^a   Wang, Jingze ^b   Sun, Bo ^b   Zhang, Yajing ^b   Zhu, Jin ^b   Li, Changling ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b INSTITUTE OF ZOOLOGY   (China)

Author keywords

Alternol; Apoptosis; CDC2; CDC25C; G2M arrest; PLK1; Wee1

Indexed keywords

ALTERNOL; ANTINEOPLASTIC AGENT; FUSED HETEROCYCLIC RINGS; UNCLASSIFIED DRUG;

ALTERNARIA; ANIMAL; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL DIVISION; CELL SURVIVAL; DRUG EFFECT; DRUG SCREENING; HUMAN; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; TUMOR CELL LINE;

ALTERNARIA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; G2 PHASE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE;

EID: 38949162107     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-007-9057-4     Document Type: Article

References (31)

1. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325-2327
2. Bicher A, Sarosy G, Kohn E, Adamo DO, Davis P, Jacob J (1993) Age does not influence taxol dose intensity in recurrent carcinoma of the ovary. Cancer 71:594-600 (Pubitemid 23021256)
3. Forastiere AA (1994) Paclitaxel (Taxol) for the treatment of head and neck cancer. Semin Oncol 21:49-52
4. Gautam A, Koshkina N (2003) Paclitaxel (taxol) and taxoid derivates for lung cancer treatment: potential for aerosol delivery. Curr Cancer Drug Targets 3:287-296 (Pubitemid 36944262)
5. Bishop JF, Dewar J, Toner GC, Tattersall MH, Olver IN, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J (1997) Paclitaxel as first-line treatment for metastatic breast cancer. Oncology (Huntingt) 11:19-23 (Pubitemid 27380989)
6. Gregory RE, DeLisa AF (1993) Paclitaxel: a new antineoplastic agent for refractory ovarian cancer. Clin Pharm 12:401-415 (Pubitemid 23149973)
7. King RW, Jackson P, Kirschner MW (1994) Mitosis in transition. Cell 79:563-571 (Pubitemid 24363800)
8. Booher RN, Alfa CE, Hyams JS, Beach DH (1989) The fission yeast cdc2/cdc13/suc1 protein kinase: regulation of catalytic activity and nuclear localization. Cell 58:485-497 (Pubitemid 19203533)
9. Gould KL, Nurse P (1989) Tyrosine phosphorylation of the fission yeast cdc2 protein kinase regulates entry into mitosis. Nature (Lond.) 342:39-45
10. Coleman TR, Dunphy W (1994) Cdc2 regulatory factors. Curr Opin Cell Biol. 6:877-882 (Pubitemid 24357921)
11. 2-arrestedHep3 cells by TGFb1. Mol Carcinog 36:171-182
12. Moon SK, Jin HS, Ko CN, Kim YS, Bae HS, Lee KS, Cho KH (2005) Inhibition of human endothelial cell proliferation by Gami-Jeonggi-San (Jiawei-Zhenqi-San) is accompanied by transcriptional up-regulation of p53 and Waf1 tumor suppressor genes. J Ethnopharmacol 100:187-192
13. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277:665-667 (Pubitemid 9114288)
14. Pavletich NP (1999) Mechanisms of Cyclin-dependent kinase regulation: structures of Cdks, their Cyclin activators, and Cip and INK4 inhibitors. J Mol Biol 287:821-828
15. Rajewsky FM, Müller R (2002) DNA repair and the cell cycle as targets in cancer therapy. In: The Cancer Handbook (Chapter 97). Nature Publishing Group, London
16. Nurse P (1990) Universal control mechanism regulating onset of M-phase. Nature 344:503-508
17. Poon RY, Chau MS, Yamashita K, Hunter T (1997) The role of CDC2 feedback loop control in the DNA damage checkpoint in mammalian cells. Cancer Res 57:5168-5178 (Pubitemid 27498137)
18. Parker LL, Piwnica-Worms H (1992) Inactivation of the p34CDC2 Cyclin B complex by the human Wee1 tyrosine kinase. Science 257:1955-1957
19. Graves PR (2000) The Chk1 protein kinase and the CDC25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 275:5600-5605
20. Bunz F, Dutriaux A, Lengauer C (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497-1501 (Pubitemid 28538613)
21. Smits VA, Klompmaker R, Vallenius T, Rijksen G, Makela TP, Medema RH (2000) p21 inhibits Thr161 phosphorylation of CDC2 to enforce the G2 DNA damage checkpoint. J Biol Chem 275:30638-30643
22. Taylor WR, Stark GR (2001) Regulation of the G2/M transition by p53. Oncogene 20:1803-1815 (Pubitemid 32458690)
23. Winters ZE, Ongkeko WM, Harris AL, Norbury CJ (1998) p53 regulates CDC2 independently of inhibitory phosphorylation to reinforce radiation-induced G2 arrest in human cells. Oncogene 17:673 -684
24. McShea A, Samuel T, Eppel JT, Galloway DA, Funk JO (2000) Identification of CIP-1-associated regulator of CyclinB (CARB), a novel p21-binding protein acting in the G 2 phase of the cell cycle. J Biol Chem 275:23181-23186 (Pubitemid 30646213)
25. Smits VA (2000) Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol 2:672-676
26. Uckun FM, Dibirdik I, Qazi S (2007) Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Bioorg Med Chem 15:800-814 (Pubitemid 44895504)
27. Zhang HS, Postigo AA, Dean DC (1999) Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16 INK4a, TGFb, and contact inhibition. Cell 97:53-61
28. Armstrong JS (2006) Mitochondria: a target for cancer therapy. Br J Pharmacol 147:239-248
29. Sakahira H, Enari M, Nagata S (1998) Cleavage of CAD inhibitors in CAD activation and DNA degradation during apoptosis. Nature 391:96-99 (Pubitemid 28079223)
30. Zhan Q, Fan S, Insoo B, Guillouf C, Liebermann DA, O'Connor PM, Fornace AJ (1994) Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 9:3743-3751 (Pubitemid 24359416)
31. Burger AM, Jenkins TC, Double JA, Bibby MC (1999) Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311. Br J Cancer 81:367-375 (Pubitemid 29423720)